Core Viewpoint - The Schall Law Firm is investigating potential securities law violations by Ardent Health, Inc., focusing on misleading statements and undisclosed information that may have affected investors [2]. Financial Impact - Ardent Health, Inc. reported a $43 million reduction in revenue due to accounting changes and a $54 million increase in professional liability reserves in its Q3 2025 financial results [2]. - Following this announcement, Ardent's shares fell nearly 34% the next day [2]. Legal Action - The Schall Law Firm is encouraging shareholders who suffered losses to participate in the investigation and discuss their rights [3].

NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased Stride, Inc. (“Stride” or the “Company”) (NYSE:LRN) securities to contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost. If you suffered a loss on your Stride investments, you have until January 12, 2026 to request lead plaintiff appointment. Follow the lin ...

Core Points - A class action lawsuit has been filed against Perrigo Company plc for alleged securities fraud and unlawful business practices [1] - Investors who purchased Perrigo securities during the Class Period can apply to be Lead Plaintiff by January 16, 2026 [2] - Perrigo reported significant financial challenges, including a 50% decline in earnings per share for fiscal year 2023 due to remediation costs in its infant formula business [2] - The company's stock price has experienced significant declines following negative earnings reports and strategic announcements, including a drop of 25.2% to close at $15.10 per share on November 5, 2025, after announcing a strategic review of its infant formula business [3] Financial Performance - For fiscal year 2023, Perrigo incurred one-time cash costs of $35 million to $45 million related to production issues in its infant formula business [2] - The adjusted gross profit for the second quarter ended June 28, 2025, decreased by $30 million, or 6.9%, attributed to production variability in infant formula [3] - The stock price fell by $4.87 per share (15.14%) on February 27, 2024, and by $3.28 per share (9.8%) on May 7, 2024, following negative earnings reports [2][3]

New York, New York--(Newsfile Corp. - November 18, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of Blue Owl Capital Inc. ("Blue Owl Capital Inc.") (NYSE: OWL) concerning possible violations of federal securities laws.On November 16, 2025, the Financial Times published an article describing how "Blue Owl has blocked redemptions in one of its earliest private credit funds as it merges with a larger vehicle overseen by the asset manager in a deal that could leave investor ...

Nov 18, 2025 12:10 PM Eastern Standard Time Deadline Alert: Inspire Medical Systems, Inc. (INSP) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit Share LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP reminds investors of the upcoming January 5, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Inspire Medical Systems, Inc. ("Inspire†or the "Company†) (NYSE: INSP ...

Nov 18, 2025 12:00 PM Eastern Standard Time Deadline Alert: Telix Pharmaceuticals Limited (TLX) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit Share LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP reminds investors of the upcoming January 9, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Telix Pharmaceuticals Limited ("Telix†or the "Company†) (NASDAQ: TLX) ...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Blue Owl Capital Inc. ("Blue Owl†or the "Company†) (NYSE: OWL) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN BLUE OWL CAPITAL INC. (OWL), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by. ...

Core Viewpoint - A class action lawsuit has been filed against Perrigo Company plc for securities fraud, alleging that the company made misleading statements regarding its infant formula business and failed to disclose significant operational issues [1][11]. Summary by Sections Lawsuit Details - The lawsuit was filed in the U.S. District Court for the Southern District of New York on behalf of shareholders who acquired Perrigo securities between February 27, 2023, and November 4, 2025 [1]. - Plaintiffs are pursuing claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1]. Financial Performance and Issues - In November 2022, Perrigo acquired Nestlé's Gateway infant formula plant and the rights to the Good Start brand for $170 million [3]. - On February 27, 2024, Perrigo reported a 50% decline in earnings per share compared to the previous year, attributing this to remediation costs in the infant formula business, which were estimated to be an additional $35 million to $45 million [4]. - Following this announcement, Perrigo's share price fell by $4.87, or 15.14%, closing at $27.30 [5]. - On May 7, 2024, the company reported a 34.5% decrease in net sales for the first quarter, with gross margin declining by 90 basis points [6]. - The share price dropped by $3.28, or 9.8%, to close at $30.15 on the same day [7]. - On August 6, 2025, Perrigo disclosed that production issues led to scrapping approximately $11 million of inventory, resulting in a share price decline of $3.01, or 11.31%, to close at $23.61 [8]. - On November 5, 2025, Perrigo announced a strategic review of its infant formula business and slashed its fiscal year 2025 outlook, cutting net sales growth guidance to -2.5% to -3% from a previous expectation of 0% to 3% [9]. - The stock price fell by $5.09, or 25.2%, to close at $15.10 on the same day [10]. Allegations in the Lawsuit - The lawsuit alleges that Perrigo's management made materially false and misleading statements and failed to disclose adverse facts about the infant formula business, including: 1. Significant underinvestment in maintenance and operational improvements [11]. 2. The need for substantial capital expenditures beyond stated estimates for remediation [11]. 3. Manufacturing deficiencies in the infant formula facility [11]. 4. Overstated financial results, including earnings and cash flow [11]. 5. Misleading positive statements regarding the company's business and prospects [11].

INSP SECURITIES ALERT: BFA Law Notifies Inspire Medical Systems, Inc. Investors of Important January 5 Securities Class Action DeadlineNovember 17, 2025 3:18 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - November 17, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company's senior executives for securities fraud after a signifi ...

BYND SECURITIES ALERT: BFA Law Notifies Beyond Meat, Inc. Investors of Important Securities Class Action Investigation After Stock Plummets 23%November 17, 2025 3:18 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - November 17, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Beyond Meat, Inc. (NASDAQ: BYND) for potential violations of the federal securities laws. If you invested in Beyond Meat, you are encouraged to obt ...